Helsinn signs exclusive agreement with Mundipharma for distribution of anamorelin

11 February 2015

Swiss oncology specialist Helsinn has signed an exclusive agreement with Mundipharma to distribute and license anamorelin in Brazil and markets in the Middle East and North Africa.

Helsinn will retain all international development and regulatory and clinical development activities and the supply of anamorelin for commercial use. As part of the agreement, Mundipharma will obtain the rights to marketing, promotion, distribution and sales of anamorelin in the agreed territories. The drug is a novel, once-daily, orally-active ghrelin receptor agonist under investigation to treat the wasting syndrome cancer anorexia-cachexia syndrome in non-small cell lung cancer patients.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK